CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma

BACKGROUND: Chimeric antigen receptor NK (CAR-NK) cell therapy is one of the most promising immunotherapies. Although it has shown a significant therapeutic effect in hematologic malignancies, few successes have been obtained in solid tumors including esophageal squamous cell carcinoma (ESCC). The m...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Tingdang, Dai, Ximing, Xu, Yien, Guan, Tian, Hong, Liangli, Zaib, Tahir, Zhou, Qi, Cheng, Ke, Zhou, Xiaoling, Ma, Changchun, Sun, Pingnan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563326/
https://www.ncbi.nlm.nih.gov/pubmed/37817249
http://dx.doi.org/10.1186/s12967-023-04409-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10563326/
https://www.ncbi.nlm.nih.gov/pubmed/37817249
http://dx.doi.org/10.1186/s12967-023-04409-8

Ejemplares similares